REFERENCES CHAPTER 3

(1) WHO International Classification of Functioning, Disability and Health available at URL: http://www3.who.int/icf/icftemplate.cfm. WHO ICF Database. 2007.


REFERENCES CHAPTER 5

Part 1:


REFERENCES CHAPTER 5

Part 2:


68. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261-3


REFERENCES CHAPTER 9


(3) Pascual E, Sivera F. The time required for disappearance of urate crystals from synovial fluid after successful hypouricemic treatment relates to the duration of gout. Ann Rheum Dis 2007 Jan 12; [Epub ahead of print].


Roddy E, Zhang W, Doherty M. Are joints affected by gout also affected by osteoarthritis?. Ann Rheum Dis 2007 Feb 6; [Epub ahead of print].


(39) Pascual E, Castellano JA. Treatment with colchicine decreases the white cell counts in the synovial fluid of asymptomatic knees which contain monosodium urate crystals. J Rheumatol 1992;19:600–3.


FURTHER READING CHAPTER 9


REFERENCES CHAPTER 10


(52) Thomas KW, Hunninghake GW. Sarcoidosis. JAMA 2003;289:3300.


Shigehara K, Shijubo N, Ohmichi M, et al. IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J Immunol 2001;166:642.


(119) Talmadge EK Jr. Treatment of pulmonary sarcoidosis with glucocorticoids. 2007 UpToDate. www.uptodate.com


REFERENCES CHAPTER 13


(3) van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte LB. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp’s method (van der Heijde modification). The Journal of rheumatology. 1995 Sep;22(9):1792-6.


(13) Conaghan PG, Ostergaard M, McGonagle D, O’Connor P, Emery P. The validity and predictive value of magnetic resonance imaging erosions in rheumatoid arthritis:


(100) [Ikeda K, Cox S, Emery P. Aspects of early arthritis. Biological therapy in early arthritis--overtreatment or the way to go? Arthritis research & therapy. 2007;9(3):211.


REFERENCES CHAPTER 16


Greidinger EL, Hoffman RW. The appearance of U1 RNP antibody specificities in sequential autoimmune human antisera follows a characteristic order that implicates the U1-70 kd and B′/B proteins as predominant U1 RNP immunogens. Arthritis Rheum 2001;44:368–75.


REFERENCES CHAPTER 17


(17) McClain MT, Arbuckle MR, Heinlen LD, Dennis GJ, Roebuck J, Rubertone MV, Harley JB, James JA. The prevalence, onset, and clinical significance of


REFERENCES CHAPTER 18


(12) Franchin G, Diamond B. Pulse steroids: how much is enough? Autoimmunity reviews 2006; 5: 111-113


(22) Harel M, Shoenfeld Y. Predicting and preventing autoimmunity, myth or reality? Ann NY Acad Sci 2006; 1069: 322- 345


(59) Petri M, Brodsky R. High-dose cyclophosphamide and stem cell transplantation for refractory systemic lupus erythematosus. JAMA 2006; 295: 559-560


(63) Law WG, Thong BY, Lialin TY, Kong KO, Chng HH. Acute lupus myocarditis: clinical features and outcome of an oriental case series. Lupus 2005; 14: 827-831


(95) Borba EF, Guedes LK, Christmann RB, Figueired CP, Gonçalves CR, Bonfà E. Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria. Rheumatol Int 2006; May 31, e-pub ahead of print.


Isenberg DA. B cell targeted therapies in autoimmune diseases. J Rheumatol 2006;33 Suppl 77: 24-28


Armstrong DJ, McCarron MT, Wright D. SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody). Rheumatol Int 2006; 26: 771-772


(166) Cardiel MH. Randomized, placebo controlled, double blind phase iii clinical trial for the evaluation of LJP 394 (Abetimus sodium) in the treatment of patients with SLE who are at risk for renal flare. Ann Rheum Dis 2003;


(175) S Zampieri, M Alaibac, L Iaccarino, R Rondinone, A Ghirardello, P Sarzi-Puttini, A Peserico, A Doria. Tumour necrosis factor a is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. Ann Rheum Dis 2006; 65: 545-548


(177) Tyndall A, Grathwohl A. Blood and marrow stem cell transplants in autoimmune disease, a consensus report on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow transplantation (EBMT). Br J Rheumatol 1997; 36: 390-392


REFERENCES CHAPTER 19


(30) NM Shah, MA Khamashta, T Atsumi and GRV Hughes. 1998. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus; 7: 3-6


The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA; 259: 550-554

Correlation between lupus anticoagulants and anticardiolipin antibodies in patients with prolonged activated partial thromboplastin times. Am J Med; 88: 112-6

Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost; 68: 297-300

Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost; 66: 629-632


Anticardiolipin antibodies are directed against a complex antigen that includes a lipid-bound inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA; 87: 4120-4124

Complete amino-acid sequence of human β2-glycoprotein I. Proc Natl Acad Sci USA; 90: 2141-2145

Beta 2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood; 66: 1086-1092

Specificity of ELISA for antibody to β2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol; 35: 1239-1243


Anticardiolipin antibodies recognize β2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol; 154: 954-960

The antiphospholipid/cofactor syndrome: a primary variant with antibodies to β2 glycoprotein I but no antibodies detectable in standard antiphospholipid assay. Am J Med; 101: 472-481


(69) DA Horbach, E van Oort, RC Donders, RH Derksen and PG de Groot. 1996. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost; 76: 916-924


(81) JE Gardiner, MA McGann, CW Berridge, CA Fulcher, TS Zimerman and JH Griffin. 1984. Protein S as a cofactor for activated protein C in plasma and in inactivation of purified factor VIII. Circulation; 70: 205


(84) D Erkan, HW Zhang, RC Shriky and JT Merrill. 2002. Dual antibody reactivity to b2-glycoprotein I and Protein S: increased association with thrombotic events in the antiphospholipid syndrome. Lupus; 11: 215-220


(91) AL Parke, RE Weinstein, RD Bona, DB Maier and FJ Walker. 1992. The thrombotic diathesis associated with the presence of phospholipid antibodies may be due to low levels of free protein S. Am J Med; 93: 49-56


(97) T Sugi and JA McIntyre. 2001. Certain autoantibodies to phosphatidylethanolamine (aPE) recognize Factor XI and Prekallikrein independently or in addition to the kininogens. J Autoimmun; 17: 207-214


(100) DW Jones, MJ Gallimore, IJ MacKie, SL Harris and M Winter. 2000. Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII. Br J Haematol; 110: 721-726


(110) I Uthman, Z Tabbarah and AE Gharavi. 1999. Hughes syndrome associated with cytomegalovirus infection. Lupus; 8: 775-777


(135) G Vargas-Alarcon, J Granados, C Bekker, J Alcocer-Varela and D Alarcón-Segovia. 1995. Association of HLA-DR5 (possibly DRB1*1201) with the primary antiphospholipid syndrome in Mexican patients. Arthritis Rheum; 38: 1340-1343

(137) J Granados, G Vargas-Alarcon, F Andrade, H Melin-Aldana, J Alcocer-Varela and D Alarcon-Segovia. 1996. The role of HLA-DR alleles and complotypes through the ethnic barrier in systemic lupus erythematosus in Mexicans. Lupus; 5: 184-189

(138) FC Arnett, P Thiagarajan, C Ahn and JD Reveille. 1999. Associations of anti-b2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups. Arthritis Rheum; 42: 268-274


(185) HH Liou, CR Wang, HC Chou, VL Arvanov, RC Chen, YC Chang, CY Chuang, CY Chen and MC Tsai. 1994. Anticardiolipin antisera from lupus patients with seizures reduce a GABA receptor-mediated chloride current in snail neurons. Life Sci; 54: 1119-1125


(189) R Cervera, RA Asherson, J Font, M Tikly, L Pallares, A Chamorro and M Ingelmo. 1997. Chorea in the antiphospholipid syndrome: clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and recent literature. Medicine (Baltimore); 76: 203-212


(206) A Afek, Y Shoenfeld, R Manor, I Goldberg, L Ziporen, J George, S Polak-Charcon, MC Amigo, R Garcia-Torres, R Segal and J Kopolovic. 1999. Increased endothelial cell expression of alpha3beta1 integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome. Lupus; 8: 502-507


(224) KE Moss and DA Isenberg. 2001. Comparison of renal disease severity and outcome in patients with primary antiphospholipid syndrome, antiphospholipid syndrome secondary to systemic lupus erythematosus (SLE) and SLE alone. Rheumatology (Oxford); 40: 863-7


EULAR Compendium on Rheumatic Diseases


(278) R Nayar and JM Lage. 1996. Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature. Hum Pathol; 27: 201-6


(284) EN Harris and JA Spinnato. 1991. Should anticardiolipin tests be performed in otherwise healthy pregnant women? Am J Obstet Gynecol; 165: 1272-7


(299) ML Bertolaccini and MA Khamashta. 2006. Laboratory diagnosis and management challenges in the antiphospholipid syndrome. Lupus; 15: 172-8


(319) HI Brunner, WS Chan, JS Ginsberg and BM Feldman. 2002. Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome. result of a decision analysis. J Rheumatol; 29: 490-501


(322) T Avcin, R Cimaz and PL Meroni. 2002. Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations. Lupus; 11: 4-10


REFERENCES CHAPTER 20


(60) Ooi GC, Mok MY, Tsang KW. Interstitial lung disease in systemic sclerosis. Acta Radiol 2003;44:258–64.


REFERENCES CHAPTER 22


(22) Kapsogeorgou E, Manoussakis MN. 2004. The central role of epithelial cells in Sjögren’s syndrome or autoimmune epithelitis. Autoimmune Rev 3 ;S61-63


(30bis) Bave et al. Activation of the type-I interferon system in primary SS. Arthritis Rheum 2005, 52:1185-1195


REFERENCES CHAPTER 23

Part I

(1) Kussmaul A MK. Uber eine nicht bisher beschriebene eigenthumliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskelahmung einhergeht. Deutsche Archiv Klinische Medizin. 1866;1:484-518.


Part II


REFERENCES CHAPTER 25

Part I


Part II

Herman JH. Relapsing Polychondritis in UpToDate Rheumatology. www.uptodate.com 2206.


Part III


REFERENCES CHAPTER 27

Part I


Part II

(1) Cheng AS Cardiac changes in systemic amyloidosis: visualisation by magnetic resonance imaging. Int J Cardiol. 2006;113:E21-3

(2) Delgado and Mosqueda

(3) Duston et al.


Part III


(3) Ward MM. Recent improvements in survival in patients with rheumatoid arthritis: better outcomes or different study designs? Arthritis Rheum.2001;44:1467-9


(37) Greenland P, LaBree L, Azen SP Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 2004;291: 210-5


(47) Hurt-Camejo E, Paredes S, Masana L. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum 2001;44:2761-7


Part IV


(15) Bruce IN. Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford). 2005;44:1492-502


(22) Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of the first cardiovascular events. N Engl J Med 2002;347:1557-1565


Part V


(30) Microvascular function is impaired in ankylosing spondylitis and improves after TNFα blockade. Van Eijk IC, Peters MJL, Serné EH, MD, van der Horst-Bruinsma IE, Dijkmans BAC, Smulders YM, Nurmohamed MT. Submitted


REFERENCES CHAPTER 28

Part I


(3) Pasero G and Barbieri P. Palindromic rheumatism: you just have to think about it. Clinical Experimental Rheumatology 1986; 4: 197–199.


Part II


REFERENCES CHAPTER 30


[16] Hilal G, Massicotte F, Martel-Pelletier J, Fernandes JC, Pelletier JP, Lajeunesse D. Endogenous prostaglandin E2 and insulin-like growth factor 1 can modulate the
levels of parathyroid hormone receptor in human osteoarthritic osteoblasts. J Bone Miner Res. 2001 Apr;16(4):713-21.


EULAR Compendium on Rheumatic Diseases


REFERENCES CHAPTER 36


REFERENCES CHAPTER 38


Blockmans D, De Ceuninck L, Vanderschueren S et al. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia


REFERENCES CHAPTER 39

(1) Pain terms: a list with definitions and notes on usage. Recommended by the IASP Subcommittee on Taxonomy. Pain 1979;6:249.

(2) Melzack R. From the gate to the neuromatrix. Pain 1999;S6:S121–S126.


REFERENCES CHAPTER 40


REFERENCES CHAPTER 41


(32) Choy, EH, Kingsley, GH, Khoshaba, B, Pipitone, N and Scott, DL, 2005, A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs, Ann Rheum Dis, 64, 1288-93.


REFERENCES CHAPTER 42


associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis

(36) Mazzaro C, Zorat F, Caizzi M, et al. Treatment with peg-interferon alfa-2b and ribavirin of
hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol

cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum

(38) Ramos-Casals M, Font J. Mycophenolate mofetil in patients with hepatitis C virus

(39) D’Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic

pharmacokinetics in patients with hepatitis C virus-associated systemic vasculitis.

3826.


(43) Catuogno M, Rezai S, Priori R, et al. Serum sickness associated with rituximab in a
patient with hepatitis C virus-related mixed cryoglobulinaemia. Rheumatology (Oxford)

(44) Basse G, Ribes D, Kamar N, et al. Rituximab therapy for de novo mixed

(45) Cai FZ, Ahern M, Smith M. Treatment of cryoglobulinemia associated peripheral


(47) Quartuccio L, Soardo G, Romano G, et al. Rituximab treatment for glomerulonephritis in
HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids.
Rheumatology (Oxford) 2006.

antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant

(49) Basse G, Ribes D, Kamar N, et al. Rituximab therapy for mixed cryoglobulinemia in

(50) Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed

(51) Saadoun D, Rosenzwajg M, Landau D, et al. Restoration of peripheral immune
homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 2008;111:5334–
5341.


REFERENCES CHAPTER 43


(118) Carver CS. You want to measure coping but your protocol's too long: Consider the brief COPE. Int. J. Behav. Med. 1997;4:92-100.


REFERENCES CHAPTER 44


(119) Seitz WS, Kline HJ, McIlroy MB. Quantitative assessment of peripheral arterial obstruction in Raynaud’s phenomenon: Development of a predictive model of


EULAR Compendium on Rheumatic Diseases


(220) McGonagle D, Richardson C, Green M, et al. The majority of patients with rheumatoid arthritis have erosive disease at presentation when magnetic resonance imaging of the dominant hand is employed. Arthritis and Rheumatism 1996;39(9):444–444.


Additional refs not cited in text


REFERENCES CHAPTER 50


(52) Harbuz MS, Rees RG, Eckland D, Jessop DS, Brewerton D, Lightman SL. Paradoxical responses of hypothalamic corticotropin-releasing factor (CRF) messenger ribonucleic acid (mRNA) and CRF-41 peptide and adenohipophysis proopiomelanocortin mRNA during chronic inflammatory stress. Endocrinology 1992;130:1394-400.


(91) Cutolo M. Vitamin D or hormone D deficiency in autoimmune rheumatic diseases including undifferentiated connective tissue disease. Arthritis Res & Ther 2008 (in press)

(92) Cutolo M: Vitamin D and autoimmune rheumatic diseases. Rheumatology 2008 [Epub ahead of print].


